Fresenius Kabi (injectable opioids)(FRE.DE)
HQ DE30% share
pharmaceutical · input
Propofol Injectable Anesthetic (Diprivan generic)
Lipid emulsion formulation of propofol (2,6-diisopropylphenol) for IV induction and maintenance of general anesthesia and ICU sedation. Required for virtually every surgical procedure and mechanically ventilated ICU patient. During COVID-19 (spring 2020), ICU propofol demand surged ~300-400% as respiratory patients required deep sedation for mechanical ventilation; global shortage ensued. Primary US/EU manufacturers: Fresenius Kabi, Hikma, Pfizer/Hospira, Teva. Propofol formulation requires soy lecithin (lipid emulsion stabilizer) and refined soybean oil — agricultural supply chain inputs.
0
Source countries
4
Companies
1
Goods affected
0
Claims on record
What depends on it
Goods that need this input
1 essential American goods rely on propofol injectable anesthetic (diprivan generic) somewhere upstream in their supply chain.
Who makes it
Supplier companies
4 companies produce propofol injectable anesthetic (diprivan generic).
Pfizer (Hospira)
HQ US30% share
Sterile injectables (Hospira) including propofol/anesthetics.
Hikma Pharmaceuticals
HQ GB20% share
Major US/EU generic injectables maker; propofol and other sterile generics.
Teva Pharmaceutical Industries(TEVA)
HQ IL15% share
Teva Pharmaceutical Industries Ltd. (Tel Aviv Israel; NYSE: TEVA; ~$15.9B revenue 2023; world's largest generic pharmaceutical company by revenue) is a significant manufacturer and distributor of generic carboplatin injectable in the US market. Teva's API division (TAPI) and finished-dose operations supply generic oncology products including carboplatin to US hospital pharmacies. Teva experienced its own FDA enforcement actions in this period — in 2022, Teva's Irvine California facility was shut down due to contamination and sterilization failures, causing a separate streptozocin (pancreatic cancer drug) shortage. Teva's manufacturing is concentrated in Israel, India, and Eastern Europe, with US finished-dose manufacturing in North America. Teva's scale as the world's largest generic company makes it a critical backstop supplier when primary market participants face disruptions.